Xospata and quizartinib have reached the market after Novartis’ first-to-market FLT3-targeting drug Rydapt (midostaurin), which was approved in both the US and Europe for newly-diagnosed FLT3 ...

In final draft guidance NICE said that the drug is recommended for relapse or refractory FLT3 mutation-positive AML, giving patients an alternative to chemotherapy and its unpleasant side effects ...